Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study
Richard J Young, Benjamin Solomon, June Corry, Christopher Angel, Lizbeth Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E Jackson, Alan Herschtal, Danny Rischin
Oral Oncology | ELSEVIER | Published : 2020
OBJECTIVE: Accurate determination of human papilloma virus (HPV) status is critical when identifying patients with oropharyngeal squamous cell carcinoma (OPSCC) who may be candidates for de-escalation trials. In this study we investigated whether local p16 screening, by immunohistochemistry (IHC), has high positive predictive value (PPV) for HPV status in a good prognosis HPV positive OPSCC (HPVOPSCC) population treated on a clinical trial. METHODS AND MATERIALS: Patients enrolled on the TROG 12.01 randomised trial for good prognosis HPVOPSCC were randomised based on local p16 IHC testing but subsequently had central p16 IHC and HPV RNA in situ hybridisation (HPV RNA ISH) testing. Correlatio..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council
This work was supported by the National Health and Medical Research Council (Project Grant 1047673).